Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf. 2022 Mar;21(3):435-46. doi: 10.1080/14740338.2022.1998451
Lennon RP, Griffin C, Miller EL, Dong H, Rabago D, Zgierska AE. Norovirus infections drop 49% in the United States with strict COVID-19 public health interventions. Acta Med Acad. 2020 Dec;49(3):278-80. doi: 0.5644/ama2006-124.317
Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf. 2012 Jan 1;11(1):33-44.
Mansfield CA, Johnson FR, Van Houtven GL. The missing piece: valuing averting behavior for children's ozone exposures. Resour Energy Econ. 2006 Aug;28(3):215-28.
Smith VK, Poulos C, Kim H. Treating open space as an urban amenity. Resour Energy Econ. 2002 Feb 15;24(1-2):107-29.